Robin Bechhofer
University of Wisconsin-Madison
18 Papers
628 Citations
Robin Bechhofer is an academic researcher from University of Wisconsin-Madison. The author has contributed to research in topics: Cytotoxic T cell & In vivo. The author has an hindex of 15, co-authored 18 publications. Previous affiliations of Robin Bechhofer include Hoffmann-La Roche & Loyola University Chicago.
Chat about Author
Papers
•Journal Article
Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.
Paul M. Sondel,Peter C. Kohler,Jacquelyn A. Hank,Karen H. Moore,Rosenthal Ns,Jeffrey A. Sosman,Robin Bechhofer,Barry E. Storer +7 more
TL;DR: A relatively well tolerated immunotherapy regimen using IL-2 can induce dramatic increases in lymphocyte number and augment their in vitro antitumor reactivity.
164
Repetitive Weekly Cycles of Interleukin-2. II. Clinical and Immunologic Effects of Dose, Schedule, and Addition of Indomethacin
Jeffrey A. Sosman,Peter C. Kohler,Jacquelyn A. Hank,Karen H. Moore,Robin Bechhofer,Barry E. Storer,Paul M. Sonde +6 more
TL;DR: Results suggest that continuous or combined infusion of IL-2 at 3 X 10(6) U/m2 per day on this schedule should be considered for further testing in phase II trials or in combination with other therapeutic modalities.
116
•Journal Article
In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2.
Jacquelyn A. Hank,Peter C. Kohler,Gilda Weil-Hillman,Rosenthal Ns,Karen H. Moore,Barry E. Storer,Debbie Minkoff,Jeff Bradshaw,Robin Bechhofer,Paul M. Sondel +9 more
TL;DR: It is demonstrated that the administration of IL-2 to patients with cancer induces a population of effector cells able to directly destroy natural killer-resistant target cells, when assayed in the presence ofIL-2.
87
Monitoring a clinical trial conducted under the Food and Drug Administration regulations allowing a waiver of prospective informed consent: The diaspirin cross-linked hemoglobin traumatic hemorrhagic shock efficacy trial
Roger J. Lewis,Donald A. Berry,Henry Cryer,Norman Fost,Ronald Krome,Geraldine R. Washington,Jaime Houghton,John W. Blue,Robin Bechhofer,Thomas D. Cook,Marian R. Fisher +10 more
TL;DR: Although the DCLHb trial was unsuccessful in achieving its goals, the monitoring process worked well and the interests of research subjects were protected by the actions of the DMC.
42
Phase 1 clinical trial of recombinant interleukin-2: a comparison of bolus and continuous intravenous infusion.
Peter C. Kohler,Jacquelyn A. Hank,Karen H. Moore,Barry E. Storer,Robin Bechhofer,Richard Hong,Paul M. Sondel +6 more
TL;DR: This study demonstrates that IL-2 can be given by CI or BI in a non-ICU setting with acceptable dose-dependent toxicity and the generation of endogenous activated PBL capable of enhanced cytotoxicity is encouraging.
34